Molecular profiling of endometrial cancer from TCGA to clinical practice

A Jamieson, JN McAlpine - Journal of the National Comprehensive …, 2023 - jnccn.org
Molecular classification provides an objective, reproducible framework for categorization of
endometrial cancers (ECs), informing prognosis and selection of therapy. Currently, the …

Lynch Syndrome and Gynecologic tumors: incidence, Prophylaxis, and management of patients with Cancer

I Capasso, A Santoro, E Lucci Cordisco, E Perrone… - Cancers, 2023 - mdpi.com
Simple Summary Lynch syndrome (LS) is a genetic condition predisposing to a variety of
tumors, including endometrial (EC) and ovarian cancers (OC), with cancer lifetime risk …

New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere

I Bruchim, I Capasso, A Polonsky, S Meisel… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Endometrial cancer (EC) is the only gynecologic malignancy showing
increasing trends in incidence and mortality. While standard treatment has been effective …

Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer

JFG Bejar, EY Galende, Q Zeng… - Journal for …, 2024 - pmc.ncbi.nlm.nih.gov
Background Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can
derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and …

A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancers

YL Liu, B Weigelt - Cancer, 2024 - Wiley Online Library
The DNA mismatch repair (MMR) pathway is critical for correcting DNA mismatches
generated during DNA replication. MMR‐deficiency (MMR‐D) leads to microsatellite …

[HTML][HTML] The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer

BA Martinez-Cannon, I Colombo - Cancer Drug Resistance, 2024 - oaepublish.com
The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment
landscape for numerous tumor types, including cervical and endometrial cancers. Multiple …

Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens

M Richardson, DM Chase - Current Opinion in Obstetrics and …, 2024 - journals.lww.com
The publication of the TCGA has led to significant focus on molecular subgrou**s into
POLEm, MMRd, NSMP, and p53m groups. For those patients with MMRd vs. MMRp tumors …

[HTML][HTML] Digging into phenotype change in mismatch repair deficient endometrial carcinoma and treatment with immune checkpoint inhibition, a case report

M Rey-Cárdenas, L Parrilla-Rubio… - Gynecologic …, 2023 - ncbi.nlm.nih.gov
Endometrial carcinoma (EC) is the second most common gynaecologic cancer worldwide,
when both developed and develo** countries are considered (Sung et al., 2021). In …

[PDF][PDF] Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer

Q ZENG, E Rouleau, M de Bruyn, JF Grau Bejar… - 2024 - scientiasalut.gencat.cat
Background Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can
derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and …

[PDF][PDF] Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer. Cancers 2023, 15, 1400

I Capasso, A Santoro, E Lucci Cordisco, E Perrone… - 2023 - academia.edu
This review provides a comprehensive update on recent evidence regarding gynecologic
tumors associated with Lynch Syndrome (LS). Endometrial cancer (EC) and ovarian cancer …